Literature DB >> 9413944

Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.

N J Brown1, S Ali, M W Reed, R Wiltrout, R C Rees.   

Abstract

The aim of the study was to establish a model of tumour microcirculation in vivo using the murine renal cell carcinoma cell line (RENCA) implanted into the mouse cremaster muscle, and subsequently to investigate the trafficking of syngeneic lymphocyte subpopulations into both the RENCA tumour and the surrounding normal cremaster muscle microcirculation. We have demonstrated that RENCA tumour cells, at a dose of 1.5 x 10(5) per 30 microl injected into the cremaster muscle, reproducibly produced a vascularized tumour suitable for in vivo microscopy at 10-14 days. Injection of fluorescently labelled effector cells (1 x 10(6)) including naive splenocytes, T-cell enriched populations and ex vivo interleukin 2 (IL-2)-activated splenocytes all migrated to and flowed through both the tumour and the normal microcirculation, with negligible adhesion. However, we observed the selective recruitment, localization and arrest of IL-2-activated splenocytes (P < 0.05) into the tumour microcirculation, and the subsequent extravasation of cells into the tumour intestitium in some instances. This did not occur with the other effector cells. We also observed the absence of leucocyte rolling in the tumour microcirculation, suggesting an impairment in adhesion molecule expression on the tumour endothelium. We have therefore established the potential of this model for defining further effector cell-tumour-endothelium interactions.

Entities:  

Mesh:

Year:  1997        PMID: 9413944      PMCID: PMC2228216          DOI: 10.1038/bjc.1997.599

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.

Authors:  R E Schwarz; N L Vujanovic; J C Hiserodt
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

2.  Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells.

Authors:  P H Basse; U Nannmark; B R Johansson; R B Herberman; R H Goldfarb
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

3.  Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution.

Authors:  A Sasaki; R K Jain; A A Maghazachi; R H Goldfarb; R B Herberman
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

4.  Comparison between 125IUdR and 51Cr as cell labels in investigations of tumor cell migration.

Authors:  P Basse; P Hokland; M Hokland
Journal:  Int J Rad Appl Instrum B       Date:  1990

Review 5.  Determinants of tumor blood flow: a review.

Authors:  R K Jain
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

6.  A comparison of the effects of photodynamic therapy on normal and tumor blood vessels in the rat microcirculation.

Authors:  M W Reed; T J Wieman; D A Schuschke; M T Tseng; F N Miller
Journal:  Radiat Res       Date:  1989-09       Impact factor: 2.841

7.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Surface characteristics, morphology, and ultrastructure of human adherent lymphokine-activated killer cells.

Authors:  R J Melder; E R Walker; R B Herberman; T L Whiteside
Journal:  J Leukoc Biol       Date:  1990-08       Impact factor: 4.962

9.  Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation.

Authors:  A Sasaki; R J Melder; T L Whiteside; R B Herberman; R K Jain
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

10.  Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.

Authors:  K Hayat; S Rodgers; L Bruce; R C Rees; K Chapman; S Reeder; M S Dorreen; E Sheridan; T Sreenivasan; B W Hancock
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.